We measured the plasma concentration of a centrally derived noradrenaline (NA) metabolite, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), in 20 cirrhotic patients (eight with (group A) and 12 without (group B) hepatic encephalopathy (HE)) and in 14 age matched healthy subjects to study if the central NA metabolism would be altered in liver cirrhosis patients, particularly in those with HE. The mean (SEM) plasma MHPG concentrations in the patient groups, group A (74.9 (8.6) pmol/l) and B (54.8 (7.2) pmol/l), were significantly (p<001) greater than in the control group (22.3 (2.0) pmol/l), and that in group A was significantly (p<0O05) greater than in group B. The plasma concentration of MHPG observed in these study subjects (n=34) correlated (r,=0 77, p<001) more strongly with the ratio of plasma catecholamine precursor amino acids (tryosine and phenylalanine) to other neutral amino acids (tryptophan, leucine, isoleucine, and valine) known to compete with catecholamine precursor amino acids for uptake into the brain than with plasma concentration of tyrosine plus phenylalanine alone (r,=0 63, p<001). In addition, the mean plasma MHPG concentrations measured in another group of eight cirrhotic patients (group C) during HE (79.3 (10.6) pmolIl) was significantly (p<0-01) greater than that measured after the recovery from HE (47.2 (5.2) pmolIl). The results suggest that the central NA metabolism may be altered in patients with liver cirrhosis, particularly in those with HE, and that the derangement in the central NA metabolism may be associated not only with an increase in plasma catecholamine precursor amino acids but also with a decrease in branched chain amino acids. 
SUMMARY
We measured the plasma concentration of a centrally derived noradrenaline (NA) metabolite, 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG), in 20 cirrhotic patients (eight with (group A) and 12 without (group B) hepatic encephalopathy (HE) ) and in 14 age matched healthy subjects to study if the central NA metabolism would be altered in liver cirrhosis patients, particularly in those with HE. The mean (SEM) plasma MHPG concentrations in the patient groups, group A (74.9 (8.6) pmol/l) and B (54.8 (7.2) pmol/l), were significantly (p<001) greater than in the control group (22.3 (2.0) pmol/l), and that in group A was significantly (p<0O05) greater than in group B. The plasma concentration of MHPG observed in these study subjects (n=34) correlated (r,=0 77, p<001) more strongly with the ratio of plasma catecholamine precursor amino acids (tryosine and phenylalanine) to other neutral amino acids (tryptophan, leucine, isoleucine, and valine) known to compete with catecholamine precursor amino acids for uptake into the brain than with plasma concentration of tyrosine plus phenylalanine alone (r,=0 63, p<001). In addition, the mean plasma MHPG concentrations measured in another group of eight cirrhotic patients (group C) during HE (79.3 (10.6) pmolIl) was significantly (p<0-01) greater than that measured after the recovery from HE (47.2 (5.2) pmolIl). The results suggest that the central NA metabolism may be altered in patients with liver cirrhosis, particularly in those with HE, and that the derangement in the central NA metabolism may be associated not only with an increase in plasma catecholamine precursor amino acids but also with a decrease in branched chain amino acids.
Although the pathogenesis of hepatic encephalopathy (HE) remains enigmatic, lines of evidence suggest that a derangement in the metabolism of central monoaminergic neurotransmitters -for example, noradrenaline (NA), dopamine, serotonin, may play an important role in the development of HE.'-3 Previous studies have shown that metabolites of these monoamine neurotransmitters were grossly raised in the brain and cerebrospinal fluids of animals and humans during HE.' A possible derangement in the central monoamine metabolism during HE may be associated with an augmented transport of 656 their precursor amino acids -that is, tryosine, phenylalanine, tryptophan, into the brain. Previous studies have shown that concentrations of these aromatic amino acids (AAA) were substantially raised not only in plasma but also in the cerebrospinal fluid in patients with HE.`3 To our knowledge, however, it remains unclear if a certain index of the central monoamine metabolism -for example, plasma or cerebrospinal fluid concentrations of centrally derived monoamine metabolites, obtained from cirrhotic patients with HE would significantly differ as compared with those from cirrhotic patients without HE and from normal healthy subjects.
Inasmuch as neutral amino acids -for example, AAA and branched chain amino acids (BCAA), are known to share a common transport system at the (2) plasma MHPG concentrations in these patients and controls would be not only a reflection of plasma NA precursor amino acid concentrations but also that of other neutral amino acids known to share a common transport system across the blood brain barrier.`" In the second part of the study, plasma MHPG concentrations were measured twice in the same cirrhotic patients (group C) during and after the recovery from HE to ask if plasma MHPG concentrations in these patients would show any intraindividual difference in relation to the improvement of their mental status.
The group B patients received a hospital diet containing 75 g protein, 345 g carbohydrates, and 25 g fat daily. Total caloric intake was adjusted to 1900 kcal/day during hospitalisation. The group A and C patients were prohibited from oral nutritiopal intake until their neurological manifestations disappeared. The treatment of HE for the group C patients consisted of the elimination of precipitating factors for HE, the restriction or reduction of dietary protein intake, and/or the administration of lactulose. A BCAA-enriched amino acid solution with glucose was given to the patients who were unable to tolerate sufficient protein intake to prevent a long standing negative nitrogen balance. Plasma MHPG concentrations were measured twice -that is, during and after the recovery from HE, without changing the individually required treatment schedule or under the same therapeutic background.
For each cirrhotic patient the routine laboratory examinations and coagulation tests were done. For plasma ammonia measurements, blood samples Rmol/lI were within the normal reference range in the Department of Clinical Chemistry, National Medical Center -that is, 60-120 p.mol/l, and did not significantly differ among the study groups.
The mean plasma MHPG concentrations in group A (74.9 (8.6) pmol/ml) and group B (54.8 (7.2) pmol/ ml; to convert from SI unit to a traditional unit, 1 pmollml=0-184 ng/ml) were significantly (p<0.01) greater than in the control group (22.3 (2.0) pmol/ml, Fig. 1 ). In addition, the mean plasma MHPG concentration in group A was significantly (p<005) greater than that in group B (Fig. 1) .
There was no statistically significant correlation between plasma MHPG concentrations and any of the laboratory data examined in groups A and B: correlation coefficients (r) between plasma MHPG concentrations and serum albumin concentrations, total serum bilirubin concentrations, and prothrombin time were 0 046, 0-091, and -0*019, respectively. Moreover, no significant correlation was observed between the intraindividual changes in plasma MHPG concentrations and those in any of the laboratory data during and after the recovery from HE in group C: correlation coefficients (r) for the changes in plasma MHPG versus those in albumin, total bilirubin, and prothrombin time were 0 209, 0 230, and -0053, respectively.
The mean values for plasma amino acid concentrations obtained from group A and B showed not only a significant decrease in taurine (p<001), aspartate (Table 3 ). There were no significant differences in the mean values for plasma concentrations of any amino acids between group A and B, except for alanine of which the mean plasma concentration obtained from group A was significantly (p<001) decreased as compared with that from group B (Table 3) . Relationship between the plasma MHPG concentration and the ratio of plasma tyrosine plus phenylalanine to other competing neutral amino acids (tryptophan, leucine, isoleucine, and valine) obtained from the group A and B patients and control subjects (n=34) gave a correlation coefficient (rs) of 0 77 (p<001, Fig. 2 ), whereas the plasma MHPG concentration correlated less strongly (rs= 0(63, p<001) with plasma tyrosine plus phenylalanine level.
Raised plasma concentrations of3-methoxy-4-hvdroxvphenylethyleneglycol in cirrhotic patients Clinical characteristics and laboratory data obtained from the group C patients during and after the recovery from HE were largely comparable with those obtained from the group A and B patients, respectively (Tables 1 and 2 ). The mean periods of time required for the recovery from HE was 27 (9) days (Table 2) . Among the laboratory data obtained from the group C patients during and after the recovery from HE, a significant (p<0-01) difference was observed only in the mean value for total serum bilirubin concentration (Table 2 ). In addition, there was a significant (p<0.01) difference in the mean values for plasma MHPG concentration obtained during (79.3 (10.6) pmol/l) and after the recovery from HE (47.2 (5.2) pmol/l) (Fig. 3) . The mean values for plasma MHPG concentration obtained from the group C patients with and without HE were comparable to those obtained from the cirrhotic patients with (group A), and from those without HE (group B), respectively (Figs 1 and 3 ).
Discussion
Plasma concentrations of MHPG, a major metabolite of brain NA, may reflect a functional activity of the central noradrenergic neurones.'9 Previous studies have shown that there is a highly significant correlation between plasma free MHPG concentrations and those in the brain in primates treated with drugs altering the central NA metabolism,2'9 and that a centrally acting a-adrenergic agonist, clonidine, reduces MHPG in plasma 2 (Fig. 1) . The findings obtained from this interpatient study were further validated in a prospective, intrapatient study using cirrhotic patients (group C) having the impaired hepatic function similar to the group A and B patients. Based upon these findings, we are tempted to speculate that the central NA metabolism would be deranged not only in cirrhotic patients with HE but also to some extent in patients without HE whose mean plasma MHPG concentration was significantly (p<0O1) greater than that in the control subjects (Fig. 1) . Our data appear to be in good agreement with those of recent studies`3 revealing that certain cerebral dysfunctions were detected by psychometric tests in the majority of patients with liver cirrhosis even before the first episode or between episodes of HE. The observation that there was a significant (p<0-01) difference in the mean plasma MHPG concentrations measured during and after the recovery from HE in the same cirrhotic patients (Fig. 3) may suggest that a possible alteration in the central NA metabolism in these patients coincided with the development of HE. In addition, the fact that the mean plasma MHPG concentrations during and after the recovery from HE in the group C patients were fairly comparable with those in the cirrhotic patients with HE (group A) and in those without (group B), respectively (Figs 1  and 3 ), appears to warrant the reproducibility of our observation. Whether a possible derangement in the central NA metabolism assessed by a rise in plasma MHPG concentrations in our cirrhotic patients could be a cause for HE or a result deriving from HE should remain unanswerable from the present study.
Whether the observation that plasma MHPG was raised in cirrhotic patients can be merely attributed to the derangement in the central NA metabolism appears to be an unwarranted consideration. Inasmuch as the synthesis rate of MHPG in the brain and its clearance rate in peripheral tissues -for example, hepatic sulphoconjugation and renal clearance, were not separately assessed in the present study, the above mentioned assumptive explanation for the underlying mechanism of the raised plasma MHPG concentrations in cirrhotic patients as compared with healthy controls must remain speculative. To our knowledge, however, there is no compelling evidence that the peripheral metabolism or disposal of MHPG is significantly impaired in patients with liver cirrhosis. Indeed, a previous study has demonstrated that the systemic clearance of NA was not significantly decreased in patients with decompensated liver cirrhosis as compared with healthy subjects. 35 We observed no significant correlation between plasma MHPG concentrations and any of the biochemical tests used for assessing liver function -that is, serum albumin, total serum bilirubin, and prothrombin time, in our cirrhotic patients. In addition, the mean serum creatinine concentrations obtained from all of the study groups were within normal reference range, and did not significantly differ among the study groups.
A possibility exists that the raised plasma MHPG concentrations observed in our cirrhotic patients may not necessarily be associated with an acceleration in the central NA metabolism, but may rather implicate a depletion of NA in the brain. In these patients, an increase in brain tyrosine and phenylalanine may be directed toward the overproduction of false neurotransmitters such as, octopamine and tyramine, thereby resulting in the replacement of physiological neurotransmitters such as, NA and dopamine, with these false neurotransmitters. Indeed, substantial rises of such false neurotransmitters have been reported in the cerebrospinal fluidh37 and plasma." of cirrhotic patients developing HE, whilst a significant depletion of NA in the brain of animals developing HE has been found.'6 " It still remains controversial, however, as to whether a similar change in the central NA concentration would occur during HE in man."4(4 A possible derangement in the central NA metabolism in patients with liver cirrhosis assessed by an abnormally raised plasma M H PG concentration (Figs 1 and 3 ) may be related not only to an increase in plasma catecholamine precursor amino acids -that is, tyrosine and phenylalanine, but also to a decrease in plasma BCAA. The fact that the neutral amino acid transport system in the BBB has Km values set near the physiological plasma concentrations of AAA and BCAA4' makes the brain uniquely sensitive to the effects of competition among these amino acids."'444 The Km values for AAA and BCAA obtained from the amino acid transport system in tissues other than brain (1-10 nmol/1)4' have been shown to be about 10 times greater than those values obtained from the transport system at the BBB (0. 1 to 0.5 mmol/1),4' suggesting that uptake of AAA and BCAA into peripheral tissues would be rather insensitive to the competition effects among these amino acids. A previous animal study4' showed that the brain concentration of tyrosine is more closely correlated with the ratio of plasma tyrosine to its competing neutral amino acids including BCAA than with plasma tyrosine alone. Our observation that a possible index of the central NA metabolism, plasma MHPG concentration,' 9 correlated (r,-077, 
